Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)

NCT07541287 is registered in ClinicalTrials.gov with Jade Biosciences, Inc. as lead sponsor.

NCT NCT07541287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07541287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)
Lead sponsor
Jade Biosciences, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 19, 2026
Completion date
April 30, 2029
Enrollment
30 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy